Epilepsy Drugs Market Analysis By Treatment (First Generation Anti-epileptics, Second Generation Anti-epileptics, Third Generation Anti-epileptics), And Segment Forecasts To 2024

Table of Content

Chapter 1 Executive Summary
Chapter 2 Market Snapshot
Chapter 3 Market Variables, Trends & Scope
3.1 Market segmentation & scope
3.2 Market size and growth prospects
3.2.1 Market Driver Analysis
3.2.1.1 Presence of promising pipeline for epilepsy therapeutics
3.2.1.2 Need-gap for adequate seizure control
3.2.1.3 Other drivers
3.2.2 Market Restraint Analysis
3.2.2.1 Cost of treatment
3.2.2.2 Lack of healthcare infrastructure
3.3 Penetration & growth prospect mapping
3.4 Epilepsy Drugs Market - SWOT Analysis, By Factor (political & legal, economic and technological)
3.5 Industry Analysis - Porter’s
3.6 Epilepsy Drugs Market company market share/competitive landscape, 2015
Chapter 4 Market Categorization 1: Epilepsy Drugs Estimates & Trend Analysis
4.1癫痫药物市场: Epilepsy drugs movement analysis
4.2 First Generation Anti-epileptic Drugs
4.2.1 First Generation Anti-epileptic Drugs Market, 2013 - 2024 (USD Million)
4.3 Second Generation Anti-epileptic Drugs
4.3.1 Second generation anti-epileptic drugs market, 2013 - 2024 (USD Million)
4.4 Third Generation Anti-epileptic Drugs
4.4.1 Third generation anti-epileptic drugs market, 2013 - 2024 (USD Million)
Chapter 5 Market Categorization 3: Regional Estimates & Trend Analysis, by Drug
5.1 Epilepsy drugs market share by region, 2015 & 2024
5.2 North America
5.2.1 The U.S.
5.2.2 Canada
5.3 Europe
5.3.1 Germany
5.3.2 The U.K.
5.4 Asia Pacific
5.4.1 China
5.4.2 India
5.5 Latin America
5.5.1 Brazil
5.6 MEA
5.6.1 South Africa
Chapter 6 Competitive Landscape
6.1 Strategy framework
6.2 Market participation categorization
6.3 Company Profiles
6.3.1 Johnson & Johnson
6.3.1.1公司概述
6.3.1.2 Financial Performance
6.3.1.3 Product Benchmarking
6.3.1.4 Strategic Initiatives
6.3.2 UCB Pharma, Inc.
6.3.2.1 Company Overview
6.3.2.2 Financial Performance
6.3.2.3 Product Benchmarking
6.3.2.4 Strategic Initiatives
6.3.3 Abbott Laboratories, Inc.
6.3.3.1 Company Overview
6.3.3.2 Financial Performance
6.3.3.3 Product Benchmarking
6.3.3.4 Strategic Initiatives
6.3.4 GlaxoSmithKline PLC
6.3.4.1 Company Overview
6.3.4.2 Financial Performance
6.3.4.3 Product Benchmarking
6.3.4.4 Strategic Initiatives
6.3.5 Pfizer, Inc.
6.3.5.1 Company Overview
6.3.5.2 Financial Performance
6.3.5.3 Product Benchmarking
6.3.5.4 Strategic Initiatives
6.3.6 Novartis AG
6.3.6.1 Company Overview
6.3.6.2 Financial Performance
6.3.6.3 Product Benchmarking
6.3.6.4 Strategic Initiatives
6.3.7 Sanofi Aventis S.A.
6.3.7.1 Company Overview
6.3.7.2 Financial Performance
6.3.7.3 Product Benchmarking
6.3.7.4 Strategic Initiatives
6.3.8 Shire PLC
6.3.8.1 Company Overview
6.3.8.2 Financial Performance
6.3.8.3 Product Benchmarking
6.3.8.4 Strategic Initiatives
6.3.9 Cephalon, Inc.
6.3.9.1 Company Overview
6.3.9.2 Financial Performance
6.3.9.3 Product Benchmarking
6.3.9.4 Strategic Initiatives
6.3.10 Tansna Therapeutics, Inc.
6.3.10.1 Company Overview
6.3.10.2 Financial Performance
6.3.10.3 Product Benchmarking
6.3.10.4 Strategic Initiatives

List of Tables

TABLE 1 North America epilepsy market, by drug, 2013 - 2024 (USD Million)
TABLE 2 U.S. epilepsy market, by drug, 2013 - 2024 (USD Million)
TABLE 3 Canada epilepsy market, by drug, 2013 - 2024 (USD Million)
TABLE 4 Europe epilepsy market, by drug, 2013 - 2024 (USD Million)
TABLE 5 Germany epilepsy market, by drug, 2013 - 2024 (USD Million)
TABLE 6 U.K. epilepsy market, by drug, 2013 - 2024 (USD Million)
TABLE 7 Asia Pacific epilepsy market, by drug, 2013 - 2024 (USD Million)
TABLE 8 China epilepsy market, by drug, 2013 - 2024 (USD Million)
TABLE 9 India epilepsy market, by drug, 2013 - 2024 (USD Million)
TABLE 10 Latin America epilepsy market, by drug, 2013 - 2024 (USD Million)
TABLE 11 Brazil epilepsy market, by drug, 2013 - 2024 (USD Million)
TABLE 12 MEA epilepsy market, by drug, 2013 - 2024 (USD Million)
TABLE 13 South Africa epilepsy market, by drug, 2013 - 2024 (USD Million)

List of Figures

FIG. 1 Market summary
FIG. 2 Market trends & outlook
FIG. 3 Market segmentation & scope
FIG. 4 Market driver prevalence analysis (Current & future impact)
FIG. 5 Penetration & growth prospect mapping
FIG. 6 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 7 Porter’s Five Forces Analysis
FIG. 8 Epilepsy drugs market type outlook key takeaways
FIG. 9 Epilepsy drugs market: Epilepsy drugs movement analysis
FIG. 10 Global first generation anti-epileptic drugs market, 2013 - 2024 (USD Million)
FIG. 11 Global second generation anti-epileptic drugs market, 2013 - 2024 (USD Million)
FIG. 12 Global third generation anti-epileptic drugs market, 2013 - 2024 (USD Million)
FIG. 13 Regional marketplace: Key takeaways
FIG. 14 Regional outlook, 2015 & 2024
FIG. 15 Strategy framework
FIG. 16 Participant categorization